Goldman Sachs
RGLS

Goldman Sachs’s Regulus Therapeutics RGLS Stock Holding History

Goldman Sachs’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-250
Closed -$508K – 7406
2015
Q1 		$508K Hold
250
– – ﹤0.01% 5113
2014
Q4 		$481K Buy
+250
New +$445K ﹤0.01% 5323

Other funds holding RGLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Goldman Sachs's RGLS Position: Q2 2025 in Review

Goldman Sachs sold out of Regulus Therapeutics (RGLS) in Q2 2025, closing a stake of 130,339 shares — an estimated $228K sold.

Goldman Sachs first reported a position in RGLS in Q2 2013 and held it in 25 quarters. The position peaked at $13.6M in Q1 2015. 0 funds tracked by Wall St. Rank hold RGLS as of Q2 2025.

  • Goldman Sachs reported no remaining Regulus Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Goldman Sachs sold 130,339 Regulus Therapeutics shares in Q2 2025, an estimated $228K.
  • Goldman Sachs first reported a position in Regulus Therapeutics in Q2 2013 and held it in 25 quarters.
  • Goldman Sachs's Regulus Therapeutics position peaked at $13.6M in Q1 2015.
  • 0 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2025.

Based on Goldman Sachs's 13F filing for Q2 2025, filed 14 Aug 2025.